Abstract
Simple SummaryCurrently, there is a need for prognostic tools that can stratify patients, who present with primary disease, based on whether they are at low or high risk for drug resistant and hormone-independent lethal metastatic prostate cancer. The aim of our study was to assess the potentially added value of tumor microenvironment (stroma) components for the characterisation of prostate cancer. By utilising patient derived-xenograft models we show that the molecular properties of the stroma cells are highly responsive to androgen hormone levels, and considerable ECM remodelling processes take place not only in androgen-dependent but also in androgen-independent tumor models. Transcriptomic mechanisms linked to osteotropism are conserved in bone metastatic xenografts, even when implanted in a different microenvironment. A stroma-specific gene list signature was identified, which highly correlates with Gleason score, metastasis progression and progression-free survival, and thus could potentially complement current patient stratification methods. Resistance acquisition to androgen deprivation treatment and metastasis progression are a major clinical issue associated with prostate cancer (PCa). The role of stroma during disease progression is insufficiently defined. Using transcriptomic and proteomic analyses on differentially aggressive patient-derived xenografts (PDXs), we investigated whether PCa tumors predispose their microenvironment (stroma) to a metastatic gene expression pattern. RNA sequencing was performed on the PCa PDXs BM18 (castration-sensitive) and LAPC9 (castration-resistant), representing different disease stages. Using organism-specific reference databases, the human-specific transcriptome (tumor) was identified and separated from the mouse-specific transcriptome (stroma). To identify proteomic changes in the tumor (human) versus the stroma (mouse), we performed human/mouse cell separation and subjected protein lysates to quantitative Tandem Mass Tag labeling and mass spectrometry. Tenascin C (TNC) was among the most abundant stromal genes, modulated by androgen levels in vivo and highly expressed in castration-resistant LAPC9 PDX. The tissue microarray of primary PCa samples (n = 210) showed that TNC is a negative prognostic marker of the clinical progression to recurrence or metastasis. Stroma markers of osteoblastic PCa bone metastases seven-up signature were induced in the stroma by the host organism in metastatic xenografts, indicating conserved mechanisms of tumor cells to induce a stromal premetastatic signature. A 50-gene list stroma signature was identified based on androgen-dependent responses, which shows a linear association with the Gleason score, metastasis progression and progression-free survival. Our data show that metastatic PCa PDXs, which differ in androgen sensitivity, trigger differential stroma responses, which show the metastasis risk stratification and prognostic biomarker potential.
Highlights
Bone metastases are detected in 10% of patients already at the initial diagnosis of prostate cancer (PCa) or will develop in 20–30% of the patients subjected to radical prostatectomy and androgen deprivation therapy and will progress to an advanced disease called castration-resistant prostate cancer [1]
We investigated whether metastatic PCa patient-derived xenograft models (PDXs) that differ in androgen sensitivity are triggering a differential stroma response
patient-derived xenografts (PDXs) were used in three different states: intact, post-castration and androgen replacement (24 h) (Figure 1A)
Summary
Bone metastases are detected in 10% of patients already at the initial diagnosis of prostate cancer (PCa) or will develop in 20–30% of the patients subjected to radical prostatectomy and androgen deprivation therapy and will progress to an advanced disease called castration-resistant prostate cancer [1]. Metastases are established when disseminated cancer cells colonize a secondary organ site. An important component of tumor growth is the supportive stroma: the extracellular matrix (ECM) and the nontumoral cells of the matrix microenvironment (e.g., endothelial cells, smooth muscle cells and cancer-associated fibroblasts). Upon interaction of the stroma compartment and tumor cells, the stroma responds by the secretion of growth factors, proteases and chemokines, thereby facilitating the remodeling of the ECM and, tumor cell migration and invasion [2]. Tumor cell establishment requires an abnormal microenvironment. It is unclear whether the stroma is modulated by the tumor cells or by intrinsic gene expression alterations. Understanding the mechanisms of tumor progression to the metastatic stage is necessary for the design of therapeutic and prognostic schemes
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
